Beyond the scale

The body mass index, that simple arithmetic of kilograms divided by metres squared, has long enjoyed a privileged place in medicine. It is cheap, fast and requires nothing more than a set of scales and a measuring tape. For generations, it has been the gatekeeper for diagnoses of overweight and obesity, shaping everything from insurance premiums to clinical guidelines. Yet a quiet revolution is underway, one that argues this single figure is not merely imprecise but actively misleading, and that its continued use as a blunt diagnostic tool may be harming millions.

A large international study, drawing on the health records of over 800,000 people across four countries and tracking their outcomes for up to fifteen years, has put hard numbers to a suspicion that has simmered for years. The research suggests that relying on BMI alone misses genuine, harmful obesity in somewhere between five and nine per cent of adults. Simultaneously, it wrongly labels roughly three per cent of the population as obese when they are, by any other meaningful measure, metabolically healthy. At a global scale, those percentages translate into tens of millions of individuals receiving either a false alarm or a false sense of security.

The proposed alternative is not a wholesale abandonment of BMI but rather its demotion to a screening tool, a first filter rather than a final verdict. Under this model, a very high BMI, above 40, remains a clear red flag. For everyone else, the diagnosis hinges on a second layer of evidence: the measuring tape. A waist circumference above 102 centimetres for men and 88 for women, or a waist-to-height ratio exceeding roughly 0.57, is taken as a proxy for excess visceral fat, the metabolically active tissue that nestles around internal organs and drives disease. If both BMI and waist metrics are raised, the label of obesity is applied. For those with a BMI between 25 and 30, the bar is set even higher; only if their waist measurements are also unequivocally high do they cross the diagnostic threshold.

But the most radical departure lies in a third step. The new framework insists on distinguishing between two states: clinical obesity, where excess fat has already begun to impair organ function and constitutes an active disease, and pre-clinical obesity, a state of heightened risk where the body is carrying dangerous fat but has not yet tipped into dysfunction. This is not mere semantic splitting. The study found that only a quarter to a third of those who qualify as obese under the new definition actually have clinical obesity, a group that carries a substantially higher risk of death. The reassuring flip side is that eighty to ninety per cent of those with pre-clinical obesity did not progress to the clinical disease state within a decade.

The end of a one-size-fits-all diagnosis

This stratification cuts through one of the most frustrating paradoxes of the old BMI system. Three individuals, all with a BMI of 32, could now receive three entirely different assessments. One, a muscular athlete with low body fat, would be cleared. Another, carrying excess fat but with all organ systems functioning normally, would be counselled on risk reduction and monitored. A third, whose fat tissue is already disrupting their metabolism, joints or cardiovascular system, would be treated for a disease. The framework acknowledges what clinicians have long observed: that a person can be “fat and fit” or “thin and ill”, and that the crude number on the scale conflates these radically different biological realities.

Critics will inevitably point to the added complexity. Calculating BMI takes seconds; measuring waist circumference properly requires a modicum of training and a willingness to touch a patient’s abdomen. Distinguishing pre-clinical from clinical obesity demands blood tests, a review of organ function and clinical judgement. In overstretched primary care systems, adding layers to a diagnosis can feel like a luxury. Proponents counter that this complexity is precisely the point. They argue that treating a heterogeneous condition with a homogenous label has led to both over-medicalisation and under-treatment, a costly misallocation of resources that sees some people prescribed powerful weight-loss drugs they may not need, while others are dismissed with vague advice to eat less and move more when they require intensive intervention.

Precision medicine meets public health

There is a deeper tension at play here, one that runs through all of modern medicine. The new model is a move towards precision, towards treating the individual rather than the population. It implicitly accepts that what works for public health surveillance, where a crude metric like BMI can usefully track broad trends in a million-person cohort, is not fit for purpose when a single patient sits in front of a doctor. The study’s authors are unequivocal: they believe this should now be adopted in clinics. The promise is a more judicious use of everything from lifestyle advice to GLP-1 agonists and bariatric surgery, matching the intensity of the intervention to the severity of the biological disturbance, not just the reading on the scale.

Whether this nuanced model can survive the brutal realities of a seven-minute consultation is an open question. But what the research makes plain is that our long reliance on a nineteenth-century formula has created a diagnostic tax, a systematic error that has misclassified millions. The conversation is no longer about whether BMI is imperfect, a fact widely acknowledged, but about whether we are finally ready to act on that knowledge and embrace a more cumbersome but more honest definition of what it means to carry too much fat.